Array Biopharma, Inc. (ARRY) Posts Q4 Loss of 9c/Share, Narrower than Views

Array Biopharma, Inc. (NASDAQ: ARRY) reported Q4 EPS of ($0.09), $0.04 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $20.7 million versus the consensus estimate of $21.45 million.

For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Nuvve Holdin (NVVE) Misses Q2 EPS by 1445c
• Seritage Growth Properties (SRG) Reports Q2 Loss of $0.13